These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18581119)

  • 1. Serotonin used as prognostic marker of urological tumors.
    Jungwirth N; Haeberle L; Schrott KM; Wullich B; Krause FS
    World J Urol; 2008 Oct; 26(5):499-504. PubMed ID: 18581119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
    Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum granulocyte colony-stimulating factor levels in patients with urinary bladder tumour and various urological malignancies.
    Mizutani Y; Okada Y; Terachi T; Kakehi Y; Yoshida O
    Br J Urol; 1995 Nov; 76(5):580-6. PubMed ID: 8535676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes.
    Saito K; Kihara K
    Int J Urol; 2013 Feb; 20(2):161-71. PubMed ID: 22897628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum level of immunosuppressive acidic protein in patients with urological malignancies.
    Pu YS; Tsai TC; Chiu TY; Hsieh TS; Chen J; Chen SC; Lin MC; Hsu TC
    J Formos Med Assoc; 1991 May; 90(5):498-503. PubMed ID: 1680990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Utility of the serum CRP value for assessing the prognosis and therapeutic response of urological malignancies].
    Köhler A; Eggers H; Kuczyk MA; Schrader AJ; Steffens S
    Aktuelle Urol; 2013 Nov; 44(6):452-5. PubMed ID: 24258396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
    Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
    Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
    Tonyali S; Yazici S
    Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
    Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
    Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
    Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
    Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract.
    Frick J; Aulitzky W; Fuchs D; Hausen A; Joos H; Reibnegger G; Wachter H
    Urol Int; 1985; 40(3):155-9. PubMed ID: 3874460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
    Aveta A; Cilio S; Contieri R; Spena G; Napolitano L; Manfredi C; Franco A; Crocerossa F; Cerrato C; Ferro M; Del Giudice F; Verze P; Lasorsa F; Salonia A; Nair R; Walz J; Lucarelli G; Pandolfo SD
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein in urologic cancers.
    Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
    Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
    Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
    BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases.
    Nazeer T; Ro JY; Amato RJ; Park YW; Ordonez NG; Ayala AG
    Oncol Rep; 1998; 5(6):1425-9. PubMed ID: 9769381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer.
    Lu JJ; Kakehi Y; Takahashi T; Wu XX; Yuasa T; Yoshiki T; Okada Y; Terachi T; Ogawa O
    Clin Cancer Res; 2000 Aug; 6(8):3166-71. PubMed ID: 10955799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of gamma-enolase as a tumor marker for renal cell carcinoma.
    Takashi M; Haimoto H; Tanaka J; Murase T; Kato K
    J Urol; 1989 Apr; 141(4):830-4. PubMed ID: 2648028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.